Last reviewed · How we verify
Pharmtechnology LLC — Portfolio Competitive Intelligence Brief
5 marketed
0 filed
1 Phase 3
0 Phase 2
6 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Candesartan Cilexetil 32mg | Candesartan Cilexetil 32mg | marketed | ||||
| Ibuprofen D | Ibuprofen D | marketed | ||||
| Diflucan® | Diflucan® | marketed | ||||
| Perindopril tablet | Perindopril tablet | marketed | ACE inhibitor | Angiotensin-converting enzyme (ACE) | Cardiovascular | |
| Clavamox | Clavamox | marketed | Other | |||
| Adenuric | Adenuric | phase 3 | Flavin reductase (NADPH), ATP-binding cassette sub-family G member 2, Potassium voltage-gated channel subfamily H member 2 | Other |
Therapeutic area mix
- Other · 4
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Beijing Tide Pharmaceutical Co., Ltd · 1 shared drug class
- Bioprojet · 1 shared drug class
- Boryung Pharmaceutical Co., Ltd · 1 shared drug class
- Children's Hospital of Fudan University · 1 shared drug class
- Ace Cells Lab Limited · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Pharmtechnology LLC:
- Pharmtechnology LLC pipeline updates — RSS
- Pharmtechnology LLC pipeline updates — Atom
- Pharmtechnology LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Pharmtechnology LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pharmtechnology-llc. Accessed 2026-05-13.